Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

ecancer
T

ESMO 2023 Insights: "Comparing Belzutifan With Everolimus in Pretreated Advanced Clear Cell RCC - Results From LITESPARK-005 Study"

By ecancer FEATURING Toni Choueiri
By ecancer FEATURING Toni Choueiri
63 views
October 25, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Genitourinary
28:34
Dana-Farber Cancer Institute

Prostate Cancer Highlights From ESMO 2023

Feat. M. Serzan, M. Taplin
20:40
Dana-Farber Cancer Institute

Kidney Cancer Highlights From ESMO 2023

Feat. W. Xu, T. Choueiri
02:33
Dana-Farber Cancer Institute

ESMO 2023 Summary: "Refining Risk Stratification in Patients Un…

Feat. P. Ravi
01:53
ecancer

ESMO 2023 Insights: "Results From Phase 2 LITESPARK-003 Study -…

Feat. T. Choueiri
02:23
ecancer

ESMO 2023 Insights: "Comparing Belzutifan With Everolimus in Pr…

Feat. T. Choueiri
25:33
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Prostate Cancer Updates From ASCO GU 20…

Feat. J. Berchuck, A. Choudhury
04:50
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Testicular Cancer Updates From ASCO GU …

Feat. A. Tewari
20:18
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Kidney Cancer Updates From ASCO GU 2023

Feat. W. Xu, T. Choueiri
19:48
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Bladder Cancer Updates From ASCO GU 2023

Feat. C. Mantia, J. Bellmunt
15:35
Dana-Farber Cancer Institute

Updates on the Management of Non-Clear Cell RCC

Feat. B. McGregor
14:36
OncoAlert

RCC Updates: Perioperative Treatment, Metastatic ccRCC, and Non-Clea…

Feat. T. Choueiri
14:01
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Pro…

Feat. A. D'Amico
51
Dana-Farber Cancer Institute

Lecture Summary - CARD Trial: Safety and Efficacy of Cabazitaxel in …

Feat. A. Choudhury
09:06
Dana-Farber Cancer Institute

CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Su…

Feat. A. Choudhury
03:13
Dana-Farber Cancer Institute

Outcomes of1L Ipi-Nivo & Subsequent Therapy in mRCC: Results Fro…

Feat. A. Schmidt
25:49
Dana-Farber Cancer Institute

Beyond "The Big Three" Lynch Syndrome-Linked Cancers: What…

Feat. M. Yurgelun
13:19
Dana-Farber Cancer Institute

2020 ESMO IPATential150 Trial Data on mCRPC: Does Ipatasertib Combin…

Feat. C. Sweeney
26:17
Dana-Farber Cancer Institute

Current and Emerging Agents to Treat Advanced Bladder Cancer

Feat. G. Sonpavde
10:29
Dana-Farber Cancer Institute

Study of Atezolizumab and Bevacizumab in Variant Histology RCC: Data…

Feat. B. McGregor
08:37
Dana-Farber Cancer Institute

DFCI's ASCO 2019 Update: Review of FDA's Approval of the F…

Feat. G. Sonpavde
16:32
Dana-Farber Cancer Institute

DFCI's ASCO 2019 Update on Metastatic Urothelial Carcinoma: Ana…

Feat. G. Sonpavde